The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
Open accessAbstract
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone's better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Twenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Cytokine-induced sickness behavior
Kelley, K. W., Bluthé, R.-M., Dantzer, R., Zhou, J.-H., Shen, W.-H., Johnson, R. W., & Broussard, S. R. (2003) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00077-6 · Cited by 716
Immune–neural connections: how the immune system’s response to infectious agents influences behavior
McCusker, R. H., & Kelley, K. W. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.073411 · Cited by 429
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury
Casha, S., Zygun, D., McGowan, M. D., Bains, I., Yong, V. W., & John Hurlbert, R. (2012) · Brain · doi:10.1093/brain/aws072 · Cited by 408
Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., et al. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06321.x · Cited by 397
Liu, B., Du, L., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39275-4 · Cited by 347 · cited 1×
“in the brain and spinal cord is inhibited [23].”
BackgroundThe biology of the opioid growth factor receptor (OGFr)
Zagon, I. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00160-6 · Cited by 328
Watkins, L. R., Hutchinson, M. R., Ledeboer, A., Wieseler-Frank, J., Milligan, E. D., & Maier, S. F. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.10.011 · Cited by 326
Clauw, D. J., Arnold, L. M., & McCarberg, B. H. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0206 · Cited by 303
Therapy for Lyme arthritis: Strategies for the treatment of antibiotic‐refractory arthritis
Steere, A. C., & Angelis, S. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22131 · Cited by 244
Inflammation in complex regional pain syndrome: A systematic review and meta-analysis
Parkitny, L., McAuley, J. H., Di Pietro, F., Stanton, T. R., O’Connell, N. E., Marinus, J., van Hilten, J. J., & Moseley, G. L. (2013) · Neurology · doi:10.1212/wnl.0b013e31827b1aa1 · Cited by 241
Self-citationFibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study
Younger, J., & Mackey, S. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00613.x · Cited by 211
Self-citationYounger, J., Noor, N., McCue, R., & Mackey, S. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37734 · Cited by 207
Self-citationNeurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.
Tempel, A., Gardner, E. L., & Zukin, R. S. (1985) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20595-x · Cited by 203
Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist
RESNICK, R. B., VOLAVKA, J., FREEDMAN, A. M., & THOMAS, M. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.6.646 · Cited by 197
Wieseler-Frank, J., Maier, S. F., & Watkins, L. R. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2004.08.004 · Cited by 151
Low-Dose Naltrexone Therapy Improves Active Crohn's Disease
Smith, J. P., Stock, H., Bingaman, S. I., Mauger, D. T., Rogosnitzky, M., & Zagon, I. S. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01045.x · Cited by 134
Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis
Cree, B., Kornyeyeva, E., & Goodin, D. S. (2010) · Annals of Neurology · doi:10.1002/ana.22006 · Cited by 129
Inhibitors of Microglial Neurotoxicity: Focus on Natural Products
Choi, D., Koppula, S., & Suk, K. (2011) · Molecules · doi:10.3390/molecules16021021 · Cited by 128
Smith, J. P., Bingaman, S. I., Ruggiero, F. M., Mauger, D. T., Mukherjee, A., McGovern, C. O., & Zagon, I. S. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1653-7 · Cited by 122
Lewis, S. S., Loram, L. C., Hutchinson, M. R., Li, C., Zhang, Y., Maier, S. F., Huang, Y., Rice, K. C., & Watkins, L. R. (2012) · Journal of Pain · doi:10.1016/j.jpain.2012.02.005 · Cited by 119
Low-dose naltrexone for disease prevention and quality of life
Brown, N., & Panksepp, J. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.06.048 · Cited by 108
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
Tang, C., Godfrey, T., Stawell, R. J., & Nikpour, M. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02886.x · Cited by 101
Wang, D., Sun, X., & Sadée, W. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.118810 · Cited by 99
Pharmacological characterization of LPS and opioid interactions at the toll‐like receptor 4
Stevens, C., Aravind, S., Das, S., & Davis, R. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12028 · Cited by 96
Naltrexone, opiate addiction, and endorphins
Gold, M. S., Dackis, C. A., Pottash, A. L. C., Sternbach, H. A., Annitto, W. J., Martin, D., & Dackis, M. P. (1982) · Medicinal Research Reviews · doi:10.1002/med.2610020302 · Cited by 89
Is There a Role for Cytokine Based Therapies in Fibromyalgia
Wallace, D. J. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775193208 · Cited by 85
Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, B. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510366857 · Cited by 83
Xiao, Y., Haynes, W. L., Michalek, J. E., & Russell, I. J. (2012) · Rheumatology International · doi:10.1007/s00296-012-2538-6 · Cited by 81
Signaling pathway of morphine induced acute thermal hyperalgesia in mice
Galeotti, N., Stefano, G. B., Guarna, M., Bianchi, E., & Ghelardini, C. (2006) · Pain · doi:10.1016/j.pain.2006.03.008 · Cited by 77
Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4
Fukagawa, H., Koyama, T., Kakuyama, M., & Fukuda, K. (2012) · Journal of Anesthesia · doi:10.1007/s00540-012-1469-4 · Cited by 76
Chang, R. C., Rota, C., Glover, R. E., Mason, R. P., & Hong, J. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02267-2 · Cited by 73
Donahue, R. N., McLaughlin, P. J., & Zagon, I. S. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011121 · Cited by 68
Kayser, V., Besson, J., & Guilbaud, G. (1987) · Brain Research · doi:10.1016/0006-8993(87)91338-2 · Cited by 66
Sharma, R., Rauchhaus, M., Ponikowski, P. P., Varney, S. J., Poole-Wilson, P. A., Mann, D. L., Coats, A. J. S., & Anker, S. D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00745-2 · Cited by 66
Wang, Q., Zhou, H., Gao, H., Chen, S., Chu, C., Wilson, B. C., & Hong, J. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-32 · Cited by 65
Smith, J. P., Field, D. G., Bingaman, S. I., Evans, R., & Mauger, D. T. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182702f2b · Cited by 62
Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)
Chopra, P., & Cooper, M. S. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9451-y · Cited by 62
Altered profile of chemokines in fibromyalgia patients
García, J. J., Cidoncha, A., Bote, E., Hinchado, M. D., & Ortega, E. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213506413 · Cited by 62
“Paradoxical” analgesia induced by naloxone and naltrexone
Greeley, J. D., Lê, A. D., Poulos, C. X., & Cappell, H. (1988) · Psychopharmacology · doi:10.1007/bf02431530 · Cited by 61
Naltrexone Pharmacology, Pharmacokinetics, and Metabolism: Current Status
Verebey, K., & Mulé, S. J. (1975) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952997509005661 · Cited by 60
Zhou, Q., Price, D. D., Callam, C. S., Woodruff, M. A., & Verne, G. N. (2010) · Journal of Pain · doi:10.1016/j.jpain.2010.09.002 · Cited by 50
Naltrexone and Nalmefene: Any Meaningful Difference?
Swift, R. M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.002 · Cited by 34
A Novel Inhibitory Effect of Naloxone on Macrophage Activation and Atherosclerosis Formation in Mice
Liu, S., Li, Y., Shi, G.-Y., Chen, Y.-H., Huang, C.-W., Hong, J., & Wu, H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.036 · Cited by 30
Burns, L. H., & Wang, H.-Y. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s4870 · Cited by 24
Oxycodone combined with opioid receptor antagonists: efficacy and safety
Davis, M. P., Goforth, H. W., & Gamier, P. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.783564 · Cited by 24
Effects of Long-Term Treatment with Naltrexone on Hepatic Enzyme Activity
Pini, L. A., Ferretti, C., Trenti, T., Ferrari, A., & Sternieri, E. (1991) · Drug metabolism and drug interactions · doi:10.1515/dmdi.1991.9.2.161 · Cited by 15
Cited by
Witkiewitz, K., Vowles, K. E., McCallion, E., Frohe, T., Kirouac, M., & Maisto, S. A. (2015) · Addiction · doi:10.1111/add.12964 · Cited by 99
Pain in an era of armed conflicts: prevention and treatment for warfighters and civilian casualties
George, E., Elman, I., Becerra, L., Berg, S., & Borsook, D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.002 · Cited by 18
Dara, P., Farooqui, Z., Mwale, F., Choe, C., van Wijnen, A. J., & Im, H.-J. (2023) · Biomedicines · doi:10.3390/biomedicines11061620 · Cited by 15
Metadata
- Authors
- Younger, J., Parkitny, L., & McLain, D.
- Venue
- Clinical Rheumatology
- Published
- 2014-02-15
- Volume
- 33
- Issue
- 4
- Pages
- 451-459
- ISSN
- 0770-3198 (ISSN-L)
- 1434-9949
- OpenAlex
- W2165305033
- Cited by
- 277
- References
- 47
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.